Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases with clear unmet needs. The company’s lead product candidate, Resunab, is a first-in-class, synthetic oral endocannabinoid-mimetic drug that targets chronic inflammation and fibrotic processes by triggering an endogenous pathway called “resolution of inflammation.” Resunab is currently being evaluated in three separate phase 2 clinical trials for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis (“scleroderma”) and dermatomyositis, three diseases in which inflammation and fibrosis drive morbidity and mortality. For more information, visit the company’s website at www.corbuspharma.com.